This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gori, F. Articles by Khosla, S. Search for Related Content PubMed PubMed Citation Articles by Gori, F. Articles by Khosla, S.

Effects of Androgens on the Insulin-Like Growth Factor System in an Androgen-Responsive Human Osteoblastic Cell Line

Endocrine Research Unit, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905

Address all correspondence and requests for reprints to: Sundeep Khosla, M.D., Mayo Clinic and Mayo Foundation, Endocrine Research Unit, West Joseph 5–194, 200 First Street SW, Rochester, Minnesota 55905. E-mail: khosla{at}mayo.edu

Although androgens have significant effects on bone metabolism, the mediators of their effects are still unclear. As the insulin-like growth factors (IGFs) and IGF-binding proteins (IGFBPs) have important effects on osteoblast proliferation and differentiation, we examined androgen effects on the IGF system in a conditionally immortalized human fetal osteoblastic cell line, hFOB/AR-6, which displays a mature osteoblastic phenotype and physiological levels of functional androgen receptors. The nonaromatizable androgen, 5-dihydrotestosterone (5DHT), and testosterone, but not dehydroepiandrosterone, increased IGF-I messenger RNA (mRNA) levels up to 4-fold in a dose (10^-12-10^-6 M)- and time (2–72 h)-dependent fashion. These changes were prevented by the specific androgen receptor antagonist, hydroxyflutamide. In addition, 5-DHT decreased IGFBP-4 mRNA and protein levels by 2- and 4-fold, respectively, and increased IGFBP-2 and -3 mRNA and protein levels by 6- and 7-fold (for mRNA) and 3- and 5-fold (for protein), respectively. hFOB/AR-6 cells expressed the type-I IGF receptor, but this was not regulated by 5DHT. 5DHT and IGFBP-3 specifically increased hFOB/AR-6 cell proliferation, and a monoclonal antibody specific for IGF-I blocked this effect. Thus, androgens increase the expression of IGF-I, IGFBP-2, and IGFBP-3, but decrease levels of the inhibitory IGFBP-4 in an androgen-responsive human osteoblastic cell line. Our data are consistent with the hypothesis that the effects of androgen on bone cells may be mediated at least in part by increases in IGF-I production and by differential regulation of IGFBPs.

This article has been cited by other articles:

				S. Seenundun and B. Robaire Time-Dependent Rescue of Gene Expression by Androgens in the Mouse Proximal Caput Epididymidis-1 Cell Line after Androgen Withdrawal Endocrinology, January 1, 2007; 148(1): 173 - 188. [Abstract] [Full Text] [PDF]

				T. Munzer, C. J. Rosen, S.M. Harman, K. M. Pabst, C. St. Clair, J. D. Sorkin, and M. R. Blackman Effects of GH and/or sex steroids on circulating IGF-I and IGFBPs in healthy, aged women and men Am J Physiol Endocrinol Metab, May 1, 2006; 290(5): E1006 - E1013. [Abstract] [Full Text] [PDF]

				J. D. Veldhuis, J. N. Roemmich, E. J. Richmond, and C. Y. Bowers Somatotropic and Gonadotropic Axes Linkages in Infancy, Childhood, and the Puberty-Adult Transition Endocr. Rev., April 1, 2006; 27(2): 101 - 140. [Abstract] [Full Text] [PDF]

				S. Khosla, L. J. Melton III, S. J. Achenbach, A. L. Oberg, and B. L. Riggs Hormonal and Biochemical Determinants of Trabecular Microstructure at the Ultradistal Radius in Women and Men J. Clin. Endocrinol. Metab., March 1, 2006; 91(3): 885 - 891. [Abstract] [Full Text] [PDF]

				F. Schirra, T. Suzuki, S. M. Richards, R. V. Jensen, M. Liu, M. J. Lombardi, P. Rowley, N. S. Treister, and D. A. Sullivan Androgen Control of Gene Expression in the Mouse Meibomian Gland Invest. Ophthalmol. Vis. Sci., October 1, 2005; 46(10): 3666 - 3675. [Abstract] [Full Text] [PDF]

				M. Yamaguchi, N. Ogata, Y. Shinoda, T. Akune, S. Kamekura, Y. Terauchi, T. Kadowaki, K. Hoshi, U.-I. Chung, K. Nakamura, et al. Insulin Receptor Substrate-1 Is Required for Bone Anabolic Function of Parathyroid Hormone in Mice Endocrinology, June 1, 2005; 146(6): 2620 - 2628. [Abstract] [Full Text] [PDF]

				R. P A Rooman, L. O. De Beeck, M. Martin, J. van Doorn, S. Mohan, and M. V L Du Caju Ethinylestradiol and testosterone have divergent effects on circulating IGF system components in adolescents with constitutional tall stature Eur. J. Endocrinol., April 1, 2005; 152(4): 597 - 604. [Abstract] [Full Text] [PDF]

				D. A. M. Salih, S. Mohan, Y. Kasukawa, G. Tripathi, F. A. Lovett, N. F. Anderson, E. J. Carter, J. E. Wergedal, D. J. Baylink, and J. M. Pell Insulin-Like Growth Factor-Binding Protein-5 Induces a Gender-Related Decrease in Bone Mineral Density in Transgenic Mice Endocrinology, February 1, 2005; 146(2): 931 - 940. [Abstract] [Full Text] [PDF]

				D. Vanderschueren, L. Vandenput, S. Boonen, M. K. Lindberg, R. Bouillon, and C. Ohlsson Androgens and Bone Endocr. Rev., June 1, 2004; 25(3): 389 - 425. [Abstract] [Full Text] [PDF]

				M. Centrella, T. L. McCarthy, W.-Z. Chang, D. C. Labaree, and R. B. Hochberg Estren (4-Estren-3{alpha},17{beta}-diol) Is a Prohormone that Regulates Both Androgenic and Estrogenic Transcriptional Effects through the Androgen Receptor Mol. Endocrinol., May 1, 2004; 18(5): 1120 - 1130. [Abstract] [Full Text] [PDF]

				T. Shimoaka, S. Kamekura, H. Chikuda, K. Hoshi, U.-i. Chung, T. Akune, Z. Maruyama, T. Komori, M. Matsumoto, W. Ogawa, et al. Impairment of Bone Healing by Insulin Receptor Substrate-1 Deficiency J. Biol. Chem., April 9, 2004; 279(15): 15314 - 15322. [Abstract] [Full Text] [PDF]

				Z. Weihua, J. Ekman, A. Almkvist, S. Saji, L. Wang, M. Warner, and J.-A. Gustafsson Involvement of Androgen Receptor in 17{beta}-Estradiol-Induced Cell Proliferation in Rat Uterus Biol Reprod, August 1, 2002; 67(2): 616 - 623. [Abstract] [Full Text] [PDF]

				B. L. Riggs, S. Khosla, and L. J. Melton III Sex Steroids and the Construction and Conservation of the Adult Skeleton Endocr. Rev., June 1, 2002; 23(3): 279 - 302. [Abstract] [Full Text] [PDF]

				M. W. Elmlinger, I. Mayer, D. Schnabel, B. S. Schuett, D. Diesing, G. Romalo, H. A. Wollmann, W. Weidemann, K.-D. Spindler, M. B. Ranke, et al. Decreased Expression of IGF-II and Its Binding Protein, IGF-Binding Protein-2, in Genital Skin Fibroblasts of Patients with Complete Androgen Insensitivity Syndrome Compared with Normally Virilized Males J. Clin. Endocrinol. Metab., October 1, 2001; 86(10): 4741 - 4746. [Abstract] [Full Text] [PDF]

				N. Miyakoshi, Y. Kasukawa, T. A. Linkhart, D. J. Baylink, and S. Mohan Evidence That Anabolic Effects of PTH on Bone Require IGF-I in Growing Mice Endocrinology, October 1, 2001; 142(10): 4349 - 4356. [Abstract] [Full Text] [PDF]

				G. M Prelevic Osteoporosis in men J R Soc Med, January 12, 2001; 94(12): 620 - 623. [Full Text] [PDF]

				J. L. Martin and S. L. Pattison Insulin-Like Growth Factor Binding Protein-3 Is Regulated by Dihydrotestosterone and Stimulates Deoxyribonucleic Acid Synthesis and Cell Proliferation in LNCaP Prostate Carcinoma Cells Endocrinology, July 1, 2000; 141(7): 2401 - 2409. [Abstract] [Full Text] [PDF]

				M. Holzenberger, P. Leneuve, G. Hamard, B. Ducos, L. Perin, M. Binoux, and Y. Le Bouc A Targeted Partial Invalidation of the Insulin-Like Growth Factor I Receptor Gene in Mice Causes a Postnatal Growth Deficit Endocrinology, July 1, 2000; 141(7): 2557 - 2566. [Abstract] [Full Text] [PDF]